Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles

Toshiyuki Shimada, Masakazu Ueda, Hiromitsu Jinno, Naokazu Chiba, Masahiro Wada, Junji Watanabe, Kazuhiko Ishihara, Yuukou Kitagawa

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: 2-Methacryloyloxyethyl phosphorylcholine (MPC) polymer is a suitable vehicle for paclitaxel (PTX) delivery. A new targeted therapy has been developed by conjugating epidermal growth factor (EGF) to MPC polymer and its growth inhibitory and antitumor effects on cancer cells overexpressing EGF receptors (EGFR) has been investigated. Materials and Methods: EGF was conjugated to poly [MPC-co-n-butyl methacrylate-co-p-nitrophenylo- xycarbonyl poly (ethylene glycol) methacrylate] (PMBN) and mixed with PTX. The cytotoxicity of the resulting PTX incorporated into EGF-conjugated PMBN (EGF-PMBN-PTX) on EGFR-overexpressing and EGFR-deficient cell lines was compared with PTX incorporated into PMBN alone (PMBN-PTX) and PTX alone. Suspensions of the cells were injected into nude mice subcutaneously. EGF-PMBN-PTX, PMBN- PTX, PTX or NaCl solution was injected intraperitoneally. Results: The cytotoxicity and antitumor effect of EGF-PMBN- PTX were significantly greater than those of PMBN-PTX for EGFR-overexpressing cells but not for an EGFR-deficient line. Conclusion: These results suggest that EGF-PMBN-PTX may represent a more potent targeted therapy for tumors overexpressing EGFR.

Original languageEnglish
Pages (from-to)1009-1014
Number of pages6
JournalAnticancer Research
Volume29
Issue number4
Publication statusPublished - 2009 Apr

Fingerprint

Paclitaxel
Epidermal Growth Factor
Nanoparticles
Therapeutics
Phosphorylcholine
Polymers
polymyxin B nonapeptide
Ethylene Glycol
Methacrylates
Nude Mice
ErbB Receptors
Neoplasms
Suspensions

Keywords

  • Epidermal growth factor receptor
  • MPC polymer
  • Paclitaxel
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Shimada, T., Ueda, M., Jinno, H., Chiba, N., Wada, M., Watanabe, J., ... Kitagawa, Y. (2009). Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles. Anticancer Research, 29(4), 1009-1014.

Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles. / Shimada, Toshiyuki; Ueda, Masakazu; Jinno, Hiromitsu; Chiba, Naokazu; Wada, Masahiro; Watanabe, Junji; Ishihara, Kazuhiko; Kitagawa, Yuukou.

In: Anticancer Research, Vol. 29, No. 4, 04.2009, p. 1009-1014.

Research output: Contribution to journalArticle

Shimada, T, Ueda, M, Jinno, H, Chiba, N, Wada, M, Watanabe, J, Ishihara, K & Kitagawa, Y 2009, 'Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles', Anticancer Research, vol. 29, no. 4, pp. 1009-1014.
Shimada T, Ueda M, Jinno H, Chiba N, Wada M, Watanabe J et al. Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles. Anticancer Research. 2009 Apr;29(4):1009-1014.
Shimada, Toshiyuki ; Ueda, Masakazu ; Jinno, Hiromitsu ; Chiba, Naokazu ; Wada, Masahiro ; Watanabe, Junji ; Ishihara, Kazuhiko ; Kitagawa, Yuukou. / Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles. In: Anticancer Research. 2009 ; Vol. 29, No. 4. pp. 1009-1014.
@article{ac9d1a50a820418db9043f36f806e32b,
title = "Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles",
abstract = "Background: 2-Methacryloyloxyethyl phosphorylcholine (MPC) polymer is a suitable vehicle for paclitaxel (PTX) delivery. A new targeted therapy has been developed by conjugating epidermal growth factor (EGF) to MPC polymer and its growth inhibitory and antitumor effects on cancer cells overexpressing EGF receptors (EGFR) has been investigated. Materials and Methods: EGF was conjugated to poly [MPC-co-n-butyl methacrylate-co-p-nitrophenylo- xycarbonyl poly (ethylene glycol) methacrylate] (PMBN) and mixed with PTX. The cytotoxicity of the resulting PTX incorporated into EGF-conjugated PMBN (EGF-PMBN-PTX) on EGFR-overexpressing and EGFR-deficient cell lines was compared with PTX incorporated into PMBN alone (PMBN-PTX) and PTX alone. Suspensions of the cells were injected into nude mice subcutaneously. EGF-PMBN-PTX, PMBN- PTX, PTX or NaCl solution was injected intraperitoneally. Results: The cytotoxicity and antitumor effect of EGF-PMBN- PTX were significantly greater than those of PMBN-PTX for EGFR-overexpressing cells but not for an EGFR-deficient line. Conclusion: These results suggest that EGF-PMBN-PTX may represent a more potent targeted therapy for tumors overexpressing EGFR.",
keywords = "Epidermal growth factor receptor, MPC polymer, Paclitaxel, Targeted therapy",
author = "Toshiyuki Shimada and Masakazu Ueda and Hiromitsu Jinno and Naokazu Chiba and Masahiro Wada and Junji Watanabe and Kazuhiko Ishihara and Yuukou Kitagawa",
year = "2009",
month = "4",
language = "English",
volume = "29",
pages = "1009--1014",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles

AU - Shimada, Toshiyuki

AU - Ueda, Masakazu

AU - Jinno, Hiromitsu

AU - Chiba, Naokazu

AU - Wada, Masahiro

AU - Watanabe, Junji

AU - Ishihara, Kazuhiko

AU - Kitagawa, Yuukou

PY - 2009/4

Y1 - 2009/4

N2 - Background: 2-Methacryloyloxyethyl phosphorylcholine (MPC) polymer is a suitable vehicle for paclitaxel (PTX) delivery. A new targeted therapy has been developed by conjugating epidermal growth factor (EGF) to MPC polymer and its growth inhibitory and antitumor effects on cancer cells overexpressing EGF receptors (EGFR) has been investigated. Materials and Methods: EGF was conjugated to poly [MPC-co-n-butyl methacrylate-co-p-nitrophenylo- xycarbonyl poly (ethylene glycol) methacrylate] (PMBN) and mixed with PTX. The cytotoxicity of the resulting PTX incorporated into EGF-conjugated PMBN (EGF-PMBN-PTX) on EGFR-overexpressing and EGFR-deficient cell lines was compared with PTX incorporated into PMBN alone (PMBN-PTX) and PTX alone. Suspensions of the cells were injected into nude mice subcutaneously. EGF-PMBN-PTX, PMBN- PTX, PTX or NaCl solution was injected intraperitoneally. Results: The cytotoxicity and antitumor effect of EGF-PMBN- PTX were significantly greater than those of PMBN-PTX for EGFR-overexpressing cells but not for an EGFR-deficient line. Conclusion: These results suggest that EGF-PMBN-PTX may represent a more potent targeted therapy for tumors overexpressing EGFR.

AB - Background: 2-Methacryloyloxyethyl phosphorylcholine (MPC) polymer is a suitable vehicle for paclitaxel (PTX) delivery. A new targeted therapy has been developed by conjugating epidermal growth factor (EGF) to MPC polymer and its growth inhibitory and antitumor effects on cancer cells overexpressing EGF receptors (EGFR) has been investigated. Materials and Methods: EGF was conjugated to poly [MPC-co-n-butyl methacrylate-co-p-nitrophenylo- xycarbonyl poly (ethylene glycol) methacrylate] (PMBN) and mixed with PTX. The cytotoxicity of the resulting PTX incorporated into EGF-conjugated PMBN (EGF-PMBN-PTX) on EGFR-overexpressing and EGFR-deficient cell lines was compared with PTX incorporated into PMBN alone (PMBN-PTX) and PTX alone. Suspensions of the cells were injected into nude mice subcutaneously. EGF-PMBN-PTX, PMBN- PTX, PTX or NaCl solution was injected intraperitoneally. Results: The cytotoxicity and antitumor effect of EGF-PMBN- PTX were significantly greater than those of PMBN-PTX for EGFR-overexpressing cells but not for an EGFR-deficient line. Conclusion: These results suggest that EGF-PMBN-PTX may represent a more potent targeted therapy for tumors overexpressing EGFR.

KW - Epidermal growth factor receptor

KW - MPC polymer

KW - Paclitaxel

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=64949146011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64949146011&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 1009

EP - 1014

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -